C
Constructive Bio
Realising the potential of genome rewriting to drive the next generation of bioprocesses and biopharmaceuticals
About Constructive Bio
Constructive Bio is a UK-based biotechnology company focused on re-engineering biology by creating synthetic genomes from scratch.
The company's core technology involves rewriting and reprogramming the genetic code of bacterial strains. By hijacking the cell's protein translation machinery, they can synthesize novel biopolymers and programmable biomolecules with high fidelity and scalability.
This capability allows for the creation of new classes of enzymes, pharmaceuticals, and biomaterials, targeting the drug discovery and biomanufacturing sectors.
The company operates on a B2B model, providing its technology for various commercial applications. Constructive Bio has secured significant venture funding, including a $15 million seed round and a $58 million Series A financing, to advance its genome synthesis platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 69
- Open positions
- 6
- Dealroom signal
- 92.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Synthetic Biology, Spinout, Industrial Technology, Advanced Materials, Bioeconomy, BIA Techbio UK, Techbio
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
| Role | Team | Location | Posted |
|---|---|---|---|
| Scientist/Senior Scientist Synthetic GenomicsEngineering | Engineering | Cambridge, UK | 3d ago |
| IT Manager - Part Time, 12 month contract | Cambridge, UK | 1mo ago | |
| Machine Learning Research EngineerData & AI | Data & AI | Cambridge, UK | 1mo ago |
| Speculative Applications | Cambridge, UK | 2mo ago |
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Mar 2026 | $20M | $284M | Undisclosed | ↗ |
| EARLY VCOther financing | Apr 2025 | $0 | — | LongeVC | ↗ |
Growth signals
Latest recorded traffic for Constructive Bio is 7K monthly website visits, up 52.2% over the last three months. Constructive Bio's team grew 16.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Constructive Bio in the Cambridge ecosystem
The Constructive Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Ahren Innovation Capital
General Inception
Amadeus Capital Partners
OMX Ventures
UK Research and Innovation
Series A5 investors entered at this stage
Paladin Capital Group
Jonathan Milner
+ND Capital
Fine Structure Ventures
LongeVC
Other known investors2 additional known investors
MRC Laboratory of Molecular Biology
University of Cambridge
Source: Dealroom Talent Intelligence.
See Constructive Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









